HK1207114A1 - Compositions and methods of obtaining and using endoderm and hepatocyte cells - Google Patents

Compositions and methods of obtaining and using endoderm and hepatocyte cells

Info

Publication number
HK1207114A1
HK1207114A1 HK15107688.5A HK15107688A HK1207114A1 HK 1207114 A1 HK1207114 A1 HK 1207114A1 HK 15107688 A HK15107688 A HK 15107688A HK 1207114 A1 HK1207114 A1 HK 1207114A1
Authority
HK
Hong Kong
Prior art keywords
endoderm
compositions
obtaining
methods
hepatocyte cells
Prior art date
Application number
HK15107688.5A
Other languages
English (en)
Chinese (zh)
Inventor
Estelle Doudement
Hirdesh Uppal
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1207114A1 publication Critical patent/HK1207114A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0613—Cells from endocrine organs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK15107688.5A 2012-05-23 2015-08-10 Compositions and methods of obtaining and using endoderm and hepatocyte cells HK1207114A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261650762P 2012-05-23 2012-05-23
PCT/EP2013/060372 WO2013174794A1 (fr) 2012-05-23 2013-05-21 Compositions et procédés d'obtention et d'utilisation de cellules endodermiques et d'hépatocytes

Publications (1)

Publication Number Publication Date
HK1207114A1 true HK1207114A1 (en) 2016-01-22

Family

ID=48483066

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15107688.5A HK1207114A1 (en) 2012-05-23 2015-08-10 Compositions and methods of obtaining and using endoderm and hepatocyte cells
HK16102908.9A HK1215043A1 (zh) 2012-05-23 2016-03-14 獲得和使用內胚層和肝細胞的組合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16102908.9A HK1215043A1 (zh) 2012-05-23 2016-03-14 獲得和使用內胚層和肝細胞的組合物和方法

Country Status (11)

Country Link
US (1) US20170002313A1 (fr)
EP (1) EP2852661A1 (fr)
JP (2) JP6301316B2 (fr)
KR (4) KR20160027219A (fr)
CN (2) CN104350144B (fr)
BR (1) BR112014028881A2 (fr)
CA (1) CA2868392A1 (fr)
HK (2) HK1207114A1 (fr)
MX (1) MX2014013725A (fr)
RU (1) RU2014149145A (fr)
WO (1) WO2013174794A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (fr) 2010-05-06 2011-11-10 Children's Hospital Medical Center Procédés et systèmes de conversion de cellules précurseurs en tissus intestinaux par différenciation dirigée
CN104694456B (zh) * 2013-12-06 2018-05-29 中国科学院上海药物研究所 体外培养肝样细胞的方法及采用该方法培养的优化后肝样细胞
US9404086B2 (en) * 2014-03-26 2016-08-02 Ge Healthcare Uk Limited Method for cell differentiation
EP3149156B1 (fr) 2014-05-28 2021-02-17 Children's Hospital Medical Center Procédés et systèmes de conversion de cellules précurseurs en tissus gastriques par différenciation dirigée
US11584916B2 (en) 2014-10-17 2023-02-21 Children's Hospital Medical Center Method of making in vivo human small intestine organoids from pluripotent stem cells
JP5777127B1 (ja) 2014-12-09 2015-09-09 公立大学法人横浜市立大学 原始腸内胚葉細胞及びその作製方法
JPWO2016104541A1 (ja) * 2014-12-24 2017-10-05 国立大学法人京都大学 内胚葉系細胞の製造方法、肝臓細胞の製造方法、膵臓細胞の製造方法、内胚葉系細胞の誘導促進剤、肝臓細胞の誘導促進キット、膵臓細胞の誘導促進キット、およびマイクロ流体デバイス
CN104655879A (zh) * 2015-03-05 2015-05-27 北京大学第三医院 一种应用原子力显微镜检测宫颈脱落细胞刚度的方法
JP6862347B2 (ja) * 2015-10-29 2021-04-21 学校法人順天堂 膵内分泌細胞の製造方法、及び分化転換剤
EP3452578B1 (fr) 2016-05-05 2022-08-10 Children's Hospital Medical Center Procédés de fabrication in vitro de tissu de fundus d'estomac et compositions associées à celui-ci
WO2018085419A1 (fr) * 2016-11-01 2018-05-11 Jian Feng Procédé de production de cellules souches pluripotentes naïves
CN110062764A (zh) 2016-12-05 2019-07-26 儿童医院医学中心 结肠类器官及其制备和使用方法
EP3571291A4 (fr) * 2017-01-17 2020-08-19 Agency for Science, Technology and Research Entretien et expansion de cellules progénitrices pancréatiques
WO2018152120A1 (fr) * 2017-02-14 2018-08-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Procédés d'ingénierie de cellules souches pluripotentes induites humaines pour produire un tissu hépatique
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
CN107043742A (zh) * 2017-06-20 2017-08-15 青岛金典生化器材有限公司 一种培养肝细胞的无血清培养基及其制备方法
CA3075475A1 (fr) * 2017-09-12 2019-03-21 Beth Israel Deaconess Medical Center, Inc. Compositions et methodes permettant de traiter une maladie hepatique et un dysfonctionnement hepatique
CN107937332A (zh) * 2017-12-04 2018-04-20 江苏省中医药研究院 一种诱导小鼠胰腺导管细胞向胰岛β细胞分化的方法
AU2019276514B2 (en) * 2018-05-30 2023-12-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
EP3868870A4 (fr) * 2018-10-15 2022-10-19 Evia Life Sciences Inc. Procédé de production de cellules souches/précurseurs, à l'aide d'un composé de faible poids moléculaire, à partir de cellules dérivées de tissu ou d'organe endodermique
EP4043549A2 (fr) * 2019-08-01 2022-08-17 Industry-Academic Cooperation Foundation, Yonsei University Composition de milieu pour améliorer l'activité de la protéine wnt
CN112553145B (zh) * 2020-12-25 2024-04-02 汕头大学医学院 一种高效定型内胚层细胞的诱导分化方法
CA3234762A1 (fr) * 2021-11-08 2023-05-11 Chunhui XIE Differenciation de cellules souches et composes chimiques

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5491090A (en) 1994-02-09 1996-02-13 Westvaco Corporation Embryogenic coniferous liquid suspension cultures
AU729377B2 (en) 1997-10-23 2001-02-01 Asterias Biotherapeutics, Inc. Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US7005252B1 (en) 2000-03-09 2006-02-28 Wisconsin Alumni Research Foundation Serum free cultivation of primate embryonic stem cells
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
WO2003050249A2 (fr) 2001-12-07 2003-06-19 Geron Corporation Cellules d'ilots pancreatiques provenant de cellules souches embryonnaires humaines
US20060003446A1 (en) * 2002-05-17 2006-01-05 Gordon Keller Mesoderm and definitive endoderm cell populations
WO2005036839A2 (fr) 2003-10-03 2005-04-21 Avici Systems, Inc. Voies de remplacement pour destinations de reseau
WO2005045012A1 (fr) * 2003-11-05 2005-05-19 Regents Of The University Of Minnesota Cellules souches endodermiques dans le foie et leurs procedes d'isolement
US7259011B2 (en) 2004-05-20 2007-08-21 Paul Lucas Pluripotent adult stem cells
CA2576872C (fr) 2004-08-13 2013-11-12 University Of Georgia Research Foundation, Inc. Compositions et procedes d'auto-renouvellement et de differentiation dans des cellules souches embryonnaires humaines
DE102004043256B4 (de) 2004-09-07 2013-09-19 Rheinische Friedrich-Wilhelms-Universität Bonn Skalierbarer Prozess zur Kultivierung undifferenzierter Stammzellen in Suspension
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
GB0503962D0 (en) 2005-02-25 2005-04-06 Kudos Pharm Ltd Compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
PL1991680T3 (pl) 2006-03-09 2014-01-31 Scripps Research Inst Układ do ekspresji ortogonalnych składników translacji w eubakteryjnych komórkach gospodarza
MX2008013582A (es) 2006-04-26 2009-01-19 Hoffmann La Roche Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
CA2650295C (fr) 2006-04-26 2015-12-29 Genentech, Inc. Composes inhibiteurs de la phosphoinositide 3-kinase et methodes d'utilisation connexes
CN101479274B (zh) 2006-04-26 2013-06-12 霍夫曼-拉罗奇有限公司 药用化合物
CA2650303C (fr) 2006-04-26 2015-03-24 F. Hoffmann-La Roche Ag Composes pharmaceutiques de thienopyrimidine et leur utilisation
GB0608820D0 (en) 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
AU2007254766A1 (en) * 2006-06-02 2007-12-13 University Of Georgia Research Foundation, Inc. Pancreatic and liver endoderm cells and tissue by differentiation of definitive endoderm cells obtained from human embryonic stems
CN101541953A (zh) * 2006-06-02 2009-09-23 佐治亚大学研究基金会 通过从人胚胎干细胞获得的定形内胚层细胞的分化得到胰和肝内胚层细胞及组织
ATE540029T1 (de) 2006-07-28 2012-01-15 Novartis Ag 2,4-substituierte chinazoline als lipidkinasehemmer
HUE033894T2 (en) 2006-08-23 2018-01-29 Kudos Pharm Ltd 2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors
EP2057140B1 (fr) 2006-08-24 2012-08-08 AstraZeneca AB Dérivés de la morpholino pyrimidine utiles dans le traitement de maladies prolifératives
WO2008032033A1 (fr) 2006-09-14 2008-03-20 Astrazeneca Ab Dérivés de 4-benzimidazolyl-2-morpholino-6-pipérazinylpyrimidine utilisés en tant que pi3k et inhibiteurs de mtor destinés au traitement de troubles prolifératifs
WO2008032089A1 (fr) 2006-09-14 2008-03-20 Astrazeneca Ab Dérivés de 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine utilisés comme inhibiteurs de p13k et de mtor pour le traitement de troubles prolifératifs
WO2008032041A1 (fr) 2006-09-14 2008-03-20 Astrazeneca Ab Dérivés de la pyrimidine à activité inhibitrice contre les enzymes pi3k
WO2008032091A1 (fr) 2006-09-14 2008-03-20 Astrazeneca Ab Dérivés de pyrimidine
CN101563339A (zh) 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 作为 p i 3 k和 m t o r抑制剂用于治疗增殖性疾病的 2 -苯并咪唑基 - 6 -吗啉代 - 4 - (氮杂环丁烷、吡咯烷、哌啶或氮杂)嘧啶衍生物
WO2008032036A1 (fr) 2006-09-14 2008-03-20 Astrazeneca Ab Dérivés de 6-benzimidazolyl-2-morpholino-4-(azétidine, pyrrolidine, piperidine ou azépine) pyrimidine comme inhibiteurs de pi3k et mtor pour le traitement de troubles prolifératifs
WO2008032060A1 (fr) 2006-09-14 2008-03-20 Astrazeneca Ab Dérivés de 4-benzimidaz0lyl-6-m0rph0lin0-2-pipérazinylpyrimidine utilisés comme inhibiteurs de p13k et mtor dans le traitement de troubles prolifératifs
EP2057147A1 (fr) 2006-09-14 2009-05-13 Astra Zeneca AB Dérivés de pyrimidine
CN101563340A (zh) 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物
WO2008032077A1 (fr) 2006-09-14 2008-03-20 Astrazeneca Ab Dérivés de pyrimidine
WO2008032086A1 (fr) 2006-09-14 2008-03-20 Astrazeneca Ab Dérivés de 2-benzimidazolyl-6-morpholino-4-phénylpyrimidine convenant comme inhibiteurs de pi3k et de mtor pour le traitement de troubles proliférants
WO2008032027A1 (fr) 2006-09-14 2008-03-20 Astrazeneca Ab Dérivés de pyrimidine
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
MX2009004623A (es) 2006-10-30 2009-05-15 Novartis Ag Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
WO2008073785A2 (fr) 2006-12-07 2008-06-19 Genentech, Inc. Composés inhibiteurs de la phosphoinositide 3-kinase et procédés d'utilisation
MX2009005950A (es) 2006-12-07 2009-10-12 Genentech Inc Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso.
WO2008098058A1 (fr) 2007-02-06 2008-08-14 Novartis Ag Inhibiteurs de la pi3-kinase et procédés de leur utilisation
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
AU2008237715A1 (en) 2007-04-12 2008-10-23 F. Hoffmann-La Roche Ag Pharmaceutical compounds
GB0707087D0 (en) 2007-04-12 2007-05-23 Piramed Ltd Pharmaceutical compounds
KR20100016433A (ko) 2007-04-12 2010-02-12 에프. 호프만-라 로슈 아게 포스파티딜이노시톨-3-키나제의 저해제로서의 피리미딘 유도체
AR067326A1 (es) 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
ATE510841T1 (de) 2007-06-12 2011-06-15 Hoffmann La Roche Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase
WO2008152387A1 (fr) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Dérivés de quinazoline comme inhibiteurs de pi3 kinase
WO2008152394A1 (fr) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Composés pharmaceutiques
EP2074118A2 (fr) 2007-07-09 2009-07-01 AstraZeneca AB Derives de pyrimidine trisubstitues pour le traitement de maladies proliferatives
US7893059B2 (en) 2007-09-24 2011-02-22 Genentech, Inc. Thiazolopyrimidine PI3K inhibitor compounds and methods of use
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
KR20100083170A (ko) 2007-10-16 2010-07-21 와이어쓰 엘엘씨 티에노피리미딘 및 피라졸로피리미딘 화합물 및 이의 ｍＴＯＲ 키나제 및 ＰＩ3 키나제 억제제로서의 용도
CN101835779B (zh) 2007-10-26 2014-01-29 霍夫曼-拉罗奇有限公司 作为pi3激酶抑制剂的嘌呤衍生物
GB0721095D0 (en) 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
WO2009066084A1 (fr) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2-morpholinopyrimidines et leur utilisation en tant qu'inhibiteurs de kinase pi3
WO2009070524A1 (fr) 2007-11-27 2009-06-04 Wyeth Composés de pyrrolo[3,2-d]pyrimidine et leur utilisation comme inhibiteurs de la pi3 kinase et de la mtor kinase
JP2011506560A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
WO2009080705A2 (fr) 2007-12-20 2009-07-02 Novartis Ag Composés organiques
MX2010007418A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EA201001017A1 (ru) 2008-01-15 2011-02-28 ВАЙЕТ ЭлЭлСи 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
JP5608099B2 (ja) 2008-01-30 2014-10-15 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
US20090192176A1 (en) 2008-01-30 2009-07-30 Wyeth 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
WO2009097515A2 (fr) 2008-01-30 2009-08-06 Wyeth Composés d'indole fondus-[a], leur utilisation en tant qu'inhibiteurs de mtor kinase et de pi3 kinase, et leurs synthèses
US20090227575A1 (en) 2008-03-04 2009-09-10 Wyeth 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US7928248B2 (en) 2008-03-31 2011-04-19 Genentech, Inc. Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use
KR20100135325A (ko) 2008-04-29 2010-12-24 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 도파민 신경전달의 조절제
DK3216793T3 (da) 2008-05-23 2019-05-06 Wyeth Llc Triazinforbindelser som p13-kinase- og mtor-inhibitorer
WO2009155052A1 (fr) 2008-05-28 2009-12-23 Wyeth Composés de 1h-pyrrolo[2,3-b]pyridine substituée en position 3 et composés de 1h-pyrrolo[3,2-b]pyridine substituée en position 3, leur utilisation en tant qu’inhibiteurs de kinase mtor et pi3 kinase, et leur synthèses
US20090311217A1 (en) 2008-05-28 2009-12-17 Wyeth 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
CN102105474B (zh) 2008-05-30 2014-01-08 健泰科生物技术公司 嘌呤pi3k抑制剂化合物及使用方法
WO2010002954A1 (fr) 2008-07-02 2010-01-07 Wyeth Composés (2-aryl-7h-pyrrolo[2,3-d]pyrimidine-4-yl)morpholine, leur utilisation en tant qu’inhibiteurs de la mtor kinase et de la pi3 kinase, et leurs synthèses
NZ590258A (en) 2008-07-08 2013-10-25 Intellikine Llc Kinase inhibitors and methods of use
US8358269B2 (en) 2008-07-18 2013-01-22 Intel Corporation Human interface device (HID)
WO2010011620A1 (fr) 2008-07-21 2010-01-28 Wyeth Composés 4-phénoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine et n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidine-4-amine, leur utilisation comme inhibiteurs de la mtor kinase et de la pi3 kinase, et leurs synthèses
US20100028307A1 (en) 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
MX2011001196A (es) 2008-07-31 2011-05-30 Genentech Inc Compuestos de pirimidina, composiciones y metodos de uso.
US8486961B2 (en) 2008-08-12 2013-07-16 Wyeth Llc Pyrrolo[4,3,2-de]quinolin-8-amine compounds and methods of their preparation and use
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
WO2010030727A1 (fr) 2008-09-10 2010-03-18 Wyeth Llc Composés 1h—indole substitué en position 3, 1h-pyrrolo[2,3-b]pyridine substituée en position 3 et 1h-pyrrolo[3,2-b]pyridine substituée en position 3, leur utilisation comme mtor kinase et inhibiteurs de la pi3 kinase, et leurs synthèses
US20100068204A1 (en) 2008-09-12 2010-03-18 Wyeth 4-aryloxyquinolin-2(1h)-ones as mtor kinase and pi3 kinase inhibitors, for use as anti-cancer agents
WO2010036380A1 (fr) 2008-09-26 2010-04-01 Intellikine, Inc. Inhibiteurs hétérocycliques de kinases
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8008075B2 (en) 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
ES2392488T3 (es) 2008-11-20 2012-12-11 Genentech, Inc. Compuestos inhibidores de PI3K de tipo pirazolopiridina y sus procedimientos de uso
EP2405916B1 (fr) 2009-03-12 2018-02-07 Genentech, Inc. Combinaison de composés inhibiteurs de la phosphoinositide 3-kinase et d'agents chimiothérapeutiques pour le traitement de tumeurs malignes hématopoïétiques
EP2233566A1 (fr) * 2009-03-17 2010-09-29 Vrije Universiteit Brussel Génération de cellules souches pancréatiques
CA2760791C (fr) 2009-05-07 2017-06-20 Intellikine, Inc. Composes heterocycliques et leurs utilisations
US8158625B2 (en) 2009-05-27 2012-04-17 Genentech, Inc. Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
SG175708A1 (en) 2009-05-27 2011-12-29 Genentech Inc Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
WO2010136583A2 (fr) * 2009-05-29 2010-12-02 Novo Nordisk A/S Dérivation induite d'endoderme spécifique à partir d'endoderme définitif issu de cellules hps
EP2445346A4 (fr) 2009-06-24 2012-12-05 Genentech Inc Composés pyrimidine fusionnés à oxo-hétérocycles, compositions et procédés d'utilisation
JP2012531454A (ja) 2009-07-02 2012-12-10 ノバルティス アーゲー Ｐｉ３ｋ阻害剤として有用な２−カルボキサミドシクロアミノウレア類
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US20120190059A1 (en) * 2009-07-23 2012-07-26 Beijing Huayuanbochuang Technology Co., Ltd. Methods for obtaining hepatocytes, hepatic endoderm cells and hepatic progenitor cells by induced differentiation
JPWO2011016485A1 (ja) * 2009-08-04 2013-01-10 国立大学法人 岡山大学 ｉＰＳ細胞から肝実質細胞への分化誘導方法
CA2771532C (fr) 2009-08-17 2021-03-23 Intellikine, Inc. Composes heterocycliques et leurs utilisations
CA2774807C (fr) 2009-09-28 2018-04-03 F. Hoffmann-La Roche Ag Composes de benzoxepine inhibiteurs de pi3k et leurs procedes d'utilisation
US8828990B2 (en) 2009-11-12 2014-09-09 Genentech, Inc. N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use
MX2012005463A (es) 2009-11-12 2012-09-12 Hoffmann La Roche Compuestos de purina n/9 sustituida, composiciones y metodos de uso.
WO2011064309A1 (fr) * 2009-11-25 2011-06-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Procédé de différenciation hépatique de cellules endodermiques définitives
EP2539337A1 (fr) 2010-02-22 2013-01-02 F. Hoffmann-La Roche AG Composés de pyrido[3,2-d]pyrimidine inhibiteurs de pi3k delta et procédés d'utilisation
WO2011118211A1 (fr) * 2010-03-23 2011-09-29 株式会社クラレ Procédé de culture capable de provoquer la différentiation de cellules pluripotentes de mammifères
US8048675B1 (en) 2010-05-12 2011-11-01 Ipierian, Inc. Integration-free human induced pluripotent stem cells from blood
WO2011146882A1 (fr) * 2010-05-21 2011-11-24 Intellikine, Inc. Composés chimiques, compositions et procédés pour modulation de kinases
JP5894980B2 (ja) 2010-05-24 2016-03-30 インテリカイン， エルエルシー 複素環式化合物およびその使用
US10000739B2 (en) * 2010-10-28 2018-06-19 National University Corporation Kumamoto University Method and culture medium for improving pluripotent stem cell differentiation inducing efficiency

Also Published As

Publication number Publication date
CN104350144B (zh) 2017-08-04
KR20160027217A (ko) 2016-03-09
EP2852661A1 (fr) 2015-04-01
RU2014149145A (ru) 2016-07-20
JP6301316B2 (ja) 2018-03-28
CA2868392A1 (fr) 2013-11-28
KR20160027219A (ko) 2016-03-09
MX2014013725A (es) 2015-02-10
JP2015523063A (ja) 2015-08-13
CN105062961A (zh) 2015-11-18
KR20160027218A (ko) 2016-03-09
CN104350144A (zh) 2015-02-11
WO2013174794A1 (fr) 2013-11-28
KR101761464B1 (ko) 2017-07-25
HK1215043A1 (zh) 2016-08-12
KR20150008418A (ko) 2015-01-22
BR112014028881A2 (pt) 2017-06-27
US20170002313A1 (en) 2017-01-05
JP2017113005A (ja) 2017-06-29

Similar Documents

Publication Publication Date Title
HK1215043A1 (zh) 獲得和使用內胚層和肝細胞的組合物和方法
HK1216851A1 (zh) 用於提高細胞存活力的組合物和使用該組合物的方法
HK1215785A1 (zh) 控制釋放組合物及使用方法
IL237479B (en) Methods and compositions relating to eukaryotic cell modulators
HK1210494A1 (zh) 用於細胞培養的裝置和方法
EP2836224A4 (fr) Compositions de microbiota et leurs procédés associés
EP2861612A4 (fr) Méthodes de préparation de cellules souches pluripotentes
GB201200458D0 (en) Methods of preparing cells and compositions
EP2667889A4 (fr) Compositions de wnt et procédés d'utilisation de celles-ci
HK1205185A1 (en) Methods and composition related to brown adipose-like cells
IL266965B (en) Preparations containing pancreatic progenitor cells that are not multipurpose, and methods for their preparation
HK1215719A1 (zh) 免疫抑制細胞及其製造和使用方法
ZA201406267B (en) Controlled release compositions and their methods of use
HK1210436A1 (en) Novel cell compositions and methods
EP2859071A4 (fr) Compositions chimiques et leurs procédés d'utilisation
HK1219292A1 (zh) +細胞組合物及其使用方法
EP2841164A4 (fr) Compositions appropriées au derme et méthodes d'utilisation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220524